Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy

Annals of the Rheumatic Diseases

Volumn 72, Issue 8, 2013, Pages 1362-1366

  Mori, Shunsuke ^a   Ueki, Yukitaka ^b   Akeda, Yukihiro ^c   Hirakata, Naoyuki ^b   Oribe, Motohiro ^d   Shiohira, Yoshiki ^e   Hidaka, Toshihiko ^f   Oishi, Kazunori ^g  

^a Kumamoto Saishunsou National Hospital   (Japan)

^b SASEBO CHUO HOSPITAL   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d Oribe Rheumachika Naika Clinic   (Japan)

^e Tomishiro central Hospital   (Japan)

^f Zenjinkai Shimin No Mori Hospital   (Japan)

^g NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; METHOTREXATE; PNEUMOCOCCUS VACCINE; PREDNISOLONE; TOCILIZUMAB;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; ASTHENIA; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYALGIA; PHAGOCYTOSIS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SEROTYPE; SINGLE DRUG DOSE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

INFECTIONS; METHOTREXATE; RHEUMATOID ARTHRITIS; VACCINATION;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY FORMATION; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; METHOTREXATE; OPSONIN PROTEINS; PHAGOCYTOSIS; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; SEROTYPING; STREPTOCOCCUS PNEUMONIAE;

EID: 84880134524     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202658     Document Type: Article

References (20)

1. Advisory Committee on Immunization Practices. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997;46:1-24.
2. Muraguchi A, Hirano T, Tang B, et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 1988;167:332-44. (Pubitemid 18073639)
3. Kopf M, Baumann H, Freer G, , et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994;368:339-42. (Pubitemid 24104268)
4. Mond JJ, Vos Q, Lees A, , et al. T cell independent antigens. Curr Opin Immunol 1995;7:349-54.
5. Dransfield MT, Nahm MH, Han MK, , et al. Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:499-505.
6. Mori S, Ueki Y, Hirakata N, , et al. Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. Ann Rheum Dis 2012;71:2006-10.
7. McCullers JA, Rehg JE. Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J Infect Dis 2002;186:341-50. (Pubitemid 34816317)
8. Peltola VT, Murti KG, McCullers JA. Influenza virus neuraminidase contributes to secondary bacterial pneumonia. J Infect Dis 2005;192:249-57. (Pubitemid 40993394)
9. Madhi SA, Klugman KP. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med 2004;10:811-13. (Pubitemid 39070852)
10. Mease PJ, Ritchlin CT, Martin RW, , et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol 2004;31:1356-61. (Pubitemid 38879202)
11. Kapetanovic MC, Saxne T, Sjoholm A, , et al. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006;45:106-11. (Pubitemid 43033885)
12. Visvanathan S, Keenan GF, Baker DG, , et al. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. J Rheumatol 2007;34:952-7. (Pubitemid 46774837)
13. Gelinck LB, van der Bijl AE, Visser LG, , et al. Synergistic immunosuppressive effect of anti-TNF combined with methotrexate on antibody responses to the 23 valent pneumococcal polysaccharide vaccine. Vaccine 2008;26:3528-33.
14. Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines. Replacement of: TRS 927, Annex 2. In: WHO Expert Committee on Biological Standardization. Geneva: World Health Organization, 2009: 1-57.
15. Kapetanovic MC, Roseman C, Jonsson G, et al. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum 2011;63:3723-32.
16. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-39.
17. Elkayam O, Paran D, Caspi D, , et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis 2002;34:147-53. (Pubitemid 34028344)
18. Coulson E, Saravanan V, Hamilton J, , et al. Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexate. Ann Rheum Dis 2011;70:1289-91.
19. Heijstek MW, Ott de Bruin LM, Bijl M, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis 2011;70:1704-12.
20. Oishi K, Yoshimine H, Watanabe H, et al. Drug-resistant genes and serotypes of pneumococcal strains of community-acquired pneumonia among adults in Japan. Respirology 2006;11:429-36. (Pubitemid 43824338)